Ibrahim Halil Sahin, MD

Ibrahim Halil Sahin, MD, is medical oncologist specializing in gastrointestinal oncology. He is extensively involved in clinical trial development for colorectal cancer and nationally recognized expert in colorectal cancer. Dr. Sahin’s clinical and research interests focus on colorectal designing clinical trials with immunotherapy and targeted therapy for patients with advanced stage colorectal cancer. He is an active member of NCI Colon Task Force and Alliance Gastrointestinal Cancer and Colorectal Cancer Committees. He also currently serves as co-chair of HCRN Gastrointestinal Clinical Trial Working Group. Board-certified in medical oncology and internal medicine, he received his medical degree from Hacettepe University School of Medicine in Ankara, Turkey.

Dr. Sahin completed two years of postdoctoral fellowship in Gastrointestinal Oncology Department/Experimental Therapeutics Department at MD Anderson Cancer Center, and an internal medicine residency at Icahn School of Medicine at Mount Sinai. He completed a hematology/oncology fellowship at Emory University School of Medicine, during which he received the ASCO Conquer Cancer Merit Award and Rochfort scholarship. In addition, Dr. Sahin was selected to participate in the AACR/ASCO Methods in Clinical Research Workshop in 2019. His focus of research in colorectal cancer is precision medicine and immunotherapeutics and he has been actively involved in drug development in this space.

University of Michigan Health participates with most health insurance plans.